Department of General Services
Procurement Division
707
(916) 375-4400 (800) 559-5529
Broadcast Date: April 29, 2009
TO: Department Directors
Procurement
& Contracting Officers (PCOs)
Purchasing
Authority Contacts (PACs)
RE:
The Department of General Services has
the following contracts in place to assist agencies in preparing for or
treating patients infected with
the H1N1 “Swine” Influenza.
1.
Antiviral Supply Contracts – Purchases through these contracts are
restricted to pandemic influenza bulk pharmaceuticals and are to be dispensed
should a Pandemic Alert Period or Pandemic Period be declared by federal or
State pandemic influenza-specific public health emergency declarations.
·
Tamiflu® (oseltamivir phosphate) – Agreement No. 1-08-65-60
·
Relenza® (zanamivir) – Agreement No. 1-08-65-61
2. The Bulk Pharmaceutical Distribution
Agreement with AmerisourceBergen Drug Company (ABCD) – Agreement No.
1S-05-65-50.
3. Medical Supplies, Services and Equipment
Agreement with McKesson Medical Surgical – Agreement No. 1-08-65-65-01.
Customers can locate information
to understand and obtain key products that will be useful in helping to prevent
further spread of the flu by contacting Tony Nudo, Government Sales Manager,
McKesson Corp. at 1-630-945-7018 or 1-800-328-8111 ext. 388 or by email at tony.nudo@mckesson.com.
4. MRO Safety Supplies Contract for Gloves, N95
respirators and disinfectant products – Agreement No. 1S-06-84-01. Empire
Safety & Supply has stock in
5. Janitorial Supply contract for disinfection
products – Agreement No. 1S-06-79-55
Instructions on how to participate:
These Agreements and instructions for how
to participate can be found on the eP website at:
http://www.bidsync.com/DPX?ac=agencycontlist&foroid=307818
Additional Information on Swine Flu:
California Department of Public Health
(CDPH)
Center for Disease Control (CDC)
www.cdc.gov/swineflu/index.htm
The
Agencies are also encouraged to contact their local health departments
for additional information on product availability for the Swine Flu.
Comments or questions regarding this broadcast should be directed to the
following:
Gregory Doe,
Pharm.D.
Pharmaceutical
Program Consultant
Department
of General Services
(916)375-4533